Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.
作者信息
Rendon Adrian, Tiberi Simon, Scardigli Anna, D'Ambrosio Lia, Centis Rosella, Caminero Jose A, Migliori Giovanni Battista
机构信息
Center for Research, Prevention and Treatment of Respiratory Infections, University Hospital Dr José Eleuterio Gonzalez, Monterrey, N.L., Mexico;; Latin American Thoracic Association (ALAT).
Division of Infection, Barts Health NHS Trust, London, UK.
出版信息
J Thorac Dis. 2016 Oct;8(10):2666-2671. doi: 10.21037/jtd.2016.10.14.
Abstract
摘要
相似文献
1
Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.
J Thorac Dis. 2016 Oct;8(10):2666-2671. doi: 10.21037/jtd.2016.10.14.
2
Risk Factors for Multidrug-resistant Tuberculosis.
Acta Med Indones. 2018 Jan;50(1):1-2.
3
Genotyping and molecular detection of multidrug-resistant among tuberculosis lymphadenitis cases in Addis Ababa, Ethiopia.
New Microbes New Infect. 2017 Oct 24;21:36-41. doi: 10.1016/j.nmni.2017.10.009. eCollection 2018 Jan.
4
Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43.
5
Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
Respirology. 2013 Jan;18(1):8-21. doi: 10.1111/j.1440-1843.2012.02257.x.
6
[Multidrug-resistant tuberculosis. Additional comment: primary multidrug-resistant tuberculosis--diagnosis and treatment].
Kekkaku. 1998 Nov;73(11):687-90.
7
Classifying new anti-tuberculosis drugs: rationale and future perspectives.
Int J Infect Dis. 2017 Mar;56:181-184. doi: 10.1016/j.ijid.2016.10.026. Epub 2016 Nov 3.
8
Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Clin Infect Dis. 2008 Aug 15;47(4):496-502. doi: 10.1086/590005.
9
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.
10
Multidrug-resistant tuberculosis in Europe, 2010-2011.
Emerg Infect Dis. 2015 Mar;21(3):409-16. doi: 10.3201/eid2103.141343.
引用本文的文献
1
Synthesis, Characterisation, Biological Evaluation and In Silico Studies of Quinoline-1,2,3-Triazole-Anilines as Potential Antitubercular and Anti-HIV Agents.
Molecules. 2025 May 10;30(10):2119. doi: 10.3390/molecules30102119.
2
Drug resistance and genomic variations among Mycobacterium tuberculosis isolates from The Nile Delta, Egypt.
Sci Rep. 2024 Sep 2;14(1):20401. doi: 10.1038/s41598-024-70199-8.
3
Mycobacterial Targets for Thiourea Derivatives: Opportunities for Virtual Screening in Tuberculosis Drug Discovery.
Curr Med Chem. 2024;31(29):4703-4724. doi: 10.2174/0109298673276076231124104513.
4
The past, present and future of tuberculosis treatment.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Dec 25;51(6):657-668. doi: 10.3724/zdxbyxb-2022-0454.
5
MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature.
Biomedicines. 2022 Nov 3;10(11):2793. doi: 10.3390/biomedicines10112793.
6
Role of Antimicrobial Peptides in Treatment and Prevention of Mycobacterium Tuberculosis: A Review.
Int J Pept Res Ther. 2022;28(5):132. doi: 10.1007/s10989-022-10435-9. Epub 2022 Jul 22.
7
The whole-genome sequencing in predicting Mycobacterium tuberculosis drug susceptibility and resistance in Papua, Indonesia.
BMC Genomics. 2021 Nov 22;22(1):844. doi: 10.1186/s12864-021-08139-3.
8
Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.
Pharmaceuticals (Basel). 2021 May 13;14(5):461. doi: 10.3390/ph14050461.
9
Two Novel Mutations Conferring Isoniazid Resistance in .
Front Microbiol. 2020 Jul 15;11:1644. doi: 10.3389/fmicb.2020.01644. eCollection 2020.
10
Management of multidrug-resistant tuberculosis: main recommendations of the Brazilian guidelines.
J Bras Pneumol. 2020;46(2):e20190290. doi: 10.36416/1806-3756/e20190290. Epub 2020 May 11.
本文引用的文献
1
Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.
Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1.
2
β-Lactams against Tuberculosis--New Trick for an Old Dog?
N Engl J Med. 2016 Jul 28;375(4):393-4. doi: 10.1056/NEJMc1513236. Epub 2016 Jul 13.
3
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.
Eur Respir J. 2016 Sep;48(3):938-43. doi: 10.1183/13993003.00705-2016. Epub 2016 Jun 23.
4
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
Eur Respir J. 2016 Sep;48(3):935-8. doi: 10.1183/13993003.00637-2016. Epub 2016 Jun 10.
5
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Eur Respir J. 2016 Jun;47(6):1758-66. doi: 10.1183/13993003.00214-2016. Epub 2016 Apr 13.
6
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10.
7
Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16.
8
Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.
Eur Respir J. 2016 Feb;47(2):394-402. doi: 10.1183/13993003.01891-2015.
9
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.
Eur Respir J. 2016 Jan;47(1):333-6. doi: 10.1183/13993003.01278-2015. Epub 2015 Nov 19.
10
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.
Eur Respir J. 2015 Oct;46(4):887-93. doi: 10.1183/13993003.00432-2015.
Zotero 插件